Boron-containing proteasome inhibitors for use after primary cancer therapy
METHODS FOR CANCER THERAPY The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, (I) for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z' and Z2 are as defined herein..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 03. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HUI AI-MIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-03, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
AU2021200370 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA011322373 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA011322373 | ||
| 003 | DE-627 | ||
| 005 | 20240209082756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210601s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA011322373 | ||
| 035 | |a (EPA)AU2021200370 | ||
| 035 | |a (EPA)54554652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HUI AI-MIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Boron-containing proteasome inhibitors for use after primary cancer therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-03, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a METHODS FOR CANCER THERAPY The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, (I) for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z' and Z2 are as defined herein. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LABOTKA RICHARD |4 aut | |
| 700 | 0 | |a GUPTA NEERAJ |4 aut | |
| 700 | 0 | |a VENKATAKRISHNAN KARTHIK |4 aut | |
| 700 | 0 | |a LUI GUOHUI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 03. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:03 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/54554652/publication/AU2021200370A1?q=AU2021200370 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 03 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 03 |c 11 | ||